

Supplementary Table 1- Data of all the entered studies

First Author, Year	Country	Type of patients	Number of patients	Mean age	Age range or \pm SD	Parity*	History of BF**	OCP	Past medical history
CDC, 2009(1)	USA	R	7	32.0	26-35	100% parous	100% BF+	14.0%	---
Sakurai, 2011(2)	Japan	R	8	44.8	28-75	100% parous	---	---	0%
Lai, 2005(3)	China	R	9	45.7	32-83	33.3% parous	---	---	0%
Khalaf, 2020(4)	Egypt	R	10	28.0	22-42	---	---	---	Diabetes: 10.0%
Gunduz, 2014(5)	Turkey	P	11	35.0	24-46	---	81.8% BF+	27.3%	Gestational diabetes and hypertension: 9.0%
Akahane, 2013(6)	Japan	R	12	36.0	25-47	83.3% parous	---	0%	0%
Yau, 2010(7)	Canada	R	12	37.4	23-49	81.8% parous	---	16.6%	0%
Calis, 2014(8)	Turkey	R	13	33.0	---	46% parous	46.0% BF+	30.0%	Autoimmune dis.: 7.7%
Yukawa, 2015(9)	Japan	R	13	41.0	30-52	69.2% parous	46.2% BF+	0%	0%
Ozturk, 2009(10)	Turkey	R	14	34.5	27-41	---	---	---	---
Konan, 2012(11)	Turkey	R	15	36.0	23-49	80.0% parous	---	0%	Erythema nodosum: 13.3% Schizophrenia: 6.7% Prolactinoma: 6.7%
Ocal, 2010(12)	Turkey	R	16	34.0	24-51	100% parous	93.8% BF+	25.0%	Diabetes:12.5%
Fazzio, 2016(13)	USA	R	17	44.0	25-72	82.4% parous	---	---	0%
Freeman, 2017(14)	Turkey	R	17	31.7	23-38	85.7% parous	---	---	0%

Skandarajah, 2015(15)	Australia	R	17	40.0	17–69	76.0% parous	---	---	Diabetes: 11.8% Sarcoidosis: 5.9% History of prolactinoma: 5.9%
Al-Khaffaf, 2008(16)	United Kingdom	R	18	36.0	19–68	94.0% parous	---	28.0%	---
Bashir, 2017(17)	USA	R	18	35.3	22–55	Mean Par=2	---	22.2%	History of tuberculosis: 11.1%
Gurleyik, 2012(18)	Turkey	R	19	34.1	27–59	100% parous	79.0% BF+	42.0%	---
Postolova, 2019(19)	USA	R	19	33.5	---	89.5% parous	---	52.6%	Tenosynovitis: 5.3% Erythema nodosum: 5.3%
Al-Jarrah, 2013(20)	Oman	P	20	37.5	25–54	100% parous	100% BF+	2.0%	---
Baslaim, 2007(21)	Saudi Arabia	R	20	34.0	21–45	100% parous	100% BF+	0%	Diabetes: 15.0% Hypertension: 10.0%
Boufettal, 2012(22)	Morocco	R	20	38.1	19–66	---	55.0% BF+	60%	---
Dag, 2021(23)	Turkey	R	20	34.2	25–42	100% parous	85.0% BF+	22.2%	Diabetes: 11.1% Erythema nodosum: 11.1%
Liu, 2018(24)	China	R	22	29.0	23–44	100% parous	---	0%	Rheumatoid arthritis: 4.5% Abdominal tuberculosis: 4.5%
Neel, 2013(25)	France	R	23	39.0	25–61	74.0% parous	47.0% BF+	0%	Inflammatory myopathy: 8.7% Spondyloarthropathy: 4.3% Thyroiditis: 4.3%
Bani-Hani, 2004(26)	Jordan	R	24	34.3	11–55	91.7% parous	---	8.3%	0%
Joseph, 2014(27)	USA	R	24	34.0	21–53	95.0% parous	90.0% BF+	---	---
Kiyak, 2014(28)	Turkey	R	24	38.4	28–60	100% parous	---	0%	---
Azlina, 2003(29)	Malaysia	R	25	36.5	21–47	Mean Par=3	---	---	---

Salehi, 2017(30)	Iran	P	26	33.6	18-56	84.6% parous	88.5% BF+	---	---
Sheybani, 2015(31)	Iran	P	28	32.8	±6.2	100% parous	100% BF+	---	---
Elzahaby, 2016(32)	Egypt	R	30	33.0	23-43	100% parous	100% BF+	3.3%	0%
Montazer, 2020(33)	Iran	P	30	34.8	±9.3	100% parous	100% BF+	---	---
Pak, 2021(34)	Iran	R	30	36.7	±8.1	---	---	36.7%	Previous malignancy: 3.3% History of tuberculosis: 3.3%
Yildiz, 2015(35)	Turkey	R	30	33.0	21-50	100% parous	100% BF+	---	0%
Kayahan, 2012(36)	Turkey	R	31	35.0	27-62	---	---	16.1%	---
Lee, 2006(37)	Korea	R	31	34.2	27-57	96.8% parous	54.0% BF+	9.7%	---
Steuer, 2020(38)	USA	R	32	35.6	±5.5	90.6% parous	85.0% BF+	34.0%	---
Erozgen, 2010(39)	Turkey	R	33	35.3	22-52	97.0% parous	90.9% BF+	9.1%	---
Kehribar, 2020(40)	Turkey	R	33	38.6	±6.9	---	---	---	Hypothyroidism: 18.2% Ankylosing spondylitis: 12.1% Muscular dystrophy: 3.0%
Emre, 2018(41)	Turkey	R	34	40.3	26-70	97.0% parous	Mean BF=46	17.6%	History of tuberculosis: 5.9%
Alikhassi, 2019(42)	Iran	P	36	36.0	22-60	97.2% parous	91.7% BF+	56.0%	0%
Yildirim, 2021(43)	Turkey	P	36	35.4	±6.7	100% parous	100% BF+	---	---
Barreto, 2018(44)	USA	R	37	35.0	18-62	63.0% parous	---	17.2%	Hyperthyroidism: 2.7% Diabetes: 7.7% Sarcoidosis: 5.4%
Karanlik, 2014(45)	Turkey	R	37	35.0	18-58	Med Par=2	Mean BF=24.0	32.0%	---

Tekin, 2020(46)	Turkey	R	37	37.5	24-59	94.6% parous	---	---	---
Pourzand, 2014(47)	Iran	R	38	42.0	22-62	100% parous	---	100%	0%
Vanovcanova, 2019(48)	Slovenia	P	39	37.0	36-40	100% parous	30.8% BF+	---	---
Oak, 2021(49)	India	P	40	33.0	27-47	96.7% parous	BF Range 5-24	0%	Autoimmune dis.: 2.5% Hypothyroidism: 10.0%
Atak, 2015(50)	Turkey	R	40	39.1	21-71	---	---	---	---
Williams, 2021(51)	USA	R	42	32.0	18-64	93.0% parous	---	---	---
Jeon, 2017(52)	Korea	R	43	36.0	---	---	16.27 BF+	11.6%	Diabetes: 4.7%
Omranipour, 2013(53)	Iran	R	43	33.5	24-49	97.7% parous	97.7% BF+	---	---
Chirappapha, 2018(54)	Thailand	R	44	38.0	21-81	68.2% parous	---	31.0%	Diabetes: 6.1% Hypertension: 6.1% History of tuberculosis: 9.1%
Oran, 2013(55)	Turkey	R	46	33.0	28-55	94.0% parous	---	22.0%	0% Hx of autoimmune dis.
Mahmodlou, 2017(56)	Iran	R	48	27.0	---	100% parous	100% BF+	100%	---
Girgin, 2015(57)	Turkey	R	49	37.7	24-57	100% parous	100% BF+	18.4%	0%
Mizrakli, 2015(58)	Turkey	R	49	34.3	±4.4	98.0% parous	93.9% BF+	12.2%	---
Pandey, 2014(59)	USA	P	49	35.0	24-67	88.0% parous	77.0% BF+	---	---
Tang, 2020(60)	USA	R	49	---	---	100% parous	---	---	---
Lin, 2021(61)	China	R	50	32.0	±6.4	98% parous	---	---	---

Altintoprak, 2015(62)	Turkey	R	52	35.7	24-48	---	---	17.8 %	Gestational diabetes: 3.8%
Tekgoz, 2020(63)	Turkey	R	53	37.2	±6.6	94.3 % parous	94.3 % BF+	22.6%	---
Seo, 2012(64)	Korea	R	58	33.5	17-47	---	---	1.7%	0%
Kundaktepe, 2021(65)	Turkey	R	64	32.7	23 - 49	92.2 % parous	64.1 % BF+	17.2%	Diabetes: 7.8% Hypertension: 3.1% Asthma: 3.1% Allergy: 1.6% Migraine: 1.6% Other: 7.8%
Deng, 2017(66)	China	R	65	31.2	19-48	Most parous	Most BF+	---	---
Helal, 2016(67)	Egypt	R	65	38.0** *	19-55	100% parous	100% BF+	18.5%	---
Yaghan, 2019(68)	Jordan	R	68	37.8	11-55	95.6 % parous	---	---	---
Zhang, 2020(69)	China	P	68	35.0	22-55	---	---	---	Diabetes: 10.3% Hypertension: 17.6%
Akcan, 2014(70)	Turkey	R	73	36.6	---	Med Par=2	---	13.5%	---
Prasad, 2017(71)	India	R	73	32.7	23-66	100% parous	---	54.8%	---
Li, 2018(72)	China	R	75	35.9	21-61	100% parous	98.7 % BF+	0%	---
Bayrak, 2021(73)	Turkey	R	77	39.2	24-81	93.5 % parous	---	---	Diabetes: 1.3% Hypothyroidism: 5.2%
Yabanoglu, 2015(74)	Turkey	R	77	36.6	28-68	Med Par=2	Mean BF=10.9	14.3%	Diabetes: 3.9% Hypertension: 7.8% Chronic obstructive lung dis.: 1.3% Chronic renal failure: 1.3% Rheumatoid arthritis: 5.2% Sjogren: 2.6% Familial Mediterranean fever: 1.3% Ankylosing spondylitis: 1.3%
Toktas, 2020(75)	Turkey	R	78	36.6	±1.4	96.2 % parous	Mean BF=22.9	11.4%	Diabetes, Hypertension, Heart dis.: 7.7%

Shojaee, 2021(76)	Iran	P	87	34.1	±7.2	---	73.6% BF+	44.9%	---
Bouton, 2015(77)	USA	R	90	33.0	22-46	Mean Par=3	---	---	---
Ozsen, 2018(78)	Turkey	R	90	34.0	21-60	---	---	---	Tuberculosis: 1.1% Sarcoidosis: 1.1%
Yücesoy, 2021(79)	Turkey	R	93	34.1	24-58	100% parous	100% BF+	14.1%	---
Co, 2018(80)	Hong Kong and China	R	102	33.0	20-54	---	---	---	Diabetes: 2.0%
Kadivar, 2016(81)	Iran	P	112	33.9	25-70	---	100% BF+	55.4%	Diabetes: 2.6%
Tan, 2019(82)	Singapore	R	113	36.2	25-63	85.0% parous	---	---	---
Davis, 2019(83)	USA	R	120	35.0	19-61	95.0% parous	---	---	---
Koksal, 2021(84)	Turkey	R	134	33.5** *	21-68	95.5% parous	95.5% BF+	24.6%	Diabetes: 3.7% Hypothyroidism: 2.0% Hypertension: 2.0% Coronary artery dis.: 1.5% Psoriasis: 1.5% Asthma: 1.5% Systemic lupus erythematosus: 0.8% Lichen planus: 0.8% Anemia: 0.8% Others: 6.7%
Wang, 2019(85)	China	R	200	38.0	---	---	95.0% BF+	---	High fasting blood sugar: 37.0%
Aghajanzadeh, 2015(86)	Iran	R	206	32.0	22-40	---	---	---	0%
Kaviani, 2019(87)	Iran	R	374	34.1	±6.7	94.7% parous	87.5% BF+	---	---
Azizi, 2020(88)	Iran	R	474	33.9	15-72	90.7% parous	82.7% BF+	38.6%	Diabetes: 6.2%
Uysal, 2017(89)	Turkey	R	720	36.0	32, 42****	92.0% parous	85.0% BF+	13%	Diabetes: 2.0% Hypertension: 4.0% Autoimmune dis.: 3.0% Coronary artery dis.: 0.4% Other: 3.0%

BF= breastfeeding; P= prospective, R= retrospective

1. Control CfD, Prevention. Idiopathic Granulomatous Mastitis in Hispanic Women-Indiana, 2006-2008. *MMWR Morbidity and mortality weekly report* (2009) 58(47):1317-21.
2. Sakurai K, Fujisaki S, Enomoto K, Amano S, Sugitani MJSt. Evaluation of Follow-up Strategies for Corticosteroid Therapy of Idiopathic Granulomatous Mastitis. (2011) 41(3):333-7.
3. Lai EC, Chan WC, Ma TK, Tang AP, Poon CS, Leong HTJtj. The Role of Conservative Treatment in Idiopathic Granulomatous Mastitis. (2005) 11(6):454-6.
4. Khalaf A, El-Shemy GGJA-AIMJ. The Myth of Idiopathic Granulomatous Mastitis. (2020) 1(11):116-23.
5. Gunduz Y, Altintoprak F, Tatli Ayhan L, Kivilcim T, Celebi FJTbj. Effect of Topical Steroid Treatment on Idiopathic Granulomatous Mastitis: Clinical and Radiologic Evaluation. (2014) 20(6):586-91.
6. Akahane K, Tsunoda N, Kato M, Noda S, Shimoyama Y, Ishigaki S, et al. Therapeutic Strategy for Granulomatous Lobular Mastitis: A Clinicopathological Study of 12 Patients. *Nagoya Journal of Medical Science* (2013) 75(3-4):193.
7. Yau FM, Macadam SA, Kuusk U, Nimmo M, Van Laeken NJAops. The Surgical Management of Granulomatous Mastitis. (2010) 64(1):9-16.
8. Çalış H, Karakoyun R, Aslaner A, Gündüz UR, Arıcı CJMSDJoBH. Management of Patients with Idiopathic Granulomatous Mastitis: Presentation of 13 Cases. (2014) 10(1).
9. Yukawa M, Watatani M, Isono S, Fujiwara Y, Tsujie M, Kitani K, et al. Management of Granulomatous Mastitis: A Series of 13 Patients Who Were Evaluated for Treatment without Corticosteroids. *International Surgery* (2015) 100(5):774-82.
10. Ozturk E, Akin M, Can MF, Ozerhan I, Kurt B, Yagci G, et al. Idiopathic Granulomatous Mastitis. (2009) 30(1):45-9.
11. Konan A, Kalyoncu U, Dogan I, Kılıç YA, Karakoç D, Akdogan A, et al. Combined Long-Term Steroid and Immunosuppressive Treatment Regimen in Granulomatous Mastitis. *Breast Care* (2012) 7(4):297-301.
12. Ocal K, Dag A, Turkmenoglu O, Kara T, Seyit H, Konca K. Granulomatous Mastitis: Clinical, Pathological Features, and Management. *The breast journal* (2010) 16(2):176-82.
13. Fazzio RT, Shah SS, Sandhu NP, Glazebrook KNJIi. Idiopathic Granulomatous Mastitis: Imaging Update and Review. (2016) 7(4):531-9.
14. Freeman C, Xia B, Wilson G, Lewis J, Khan S, Lee S, et al. Idiopathic Granulomatous Mastitis: A Diagnostic and Therapeutic Challenge. (2017) 214(4):701-6.
15. Skandarajah A, Marley LJAJoS. Idiopathic Granulomatous Mastitis: A Medical or Surgical Disease of the Breast? (2015) 85(12):979-82.
16. Al-Khaffaf B, Knox F, Bundred NJJJoTACoS. Idiopathic Granulomatous Mastitis: A 25-Year Experience. (2008) 206(2):269-73.
17. Bashir MU, Ramcharan A, Alothman S, Beaugris S, Khan SA, Sbeih MA, et al. The Enigma of Granulomatous Mastitis: A Series. (2017) 37(1):17-20.
18. Gurleyik G, Aktekin A, Aker F, Karagulle H, Saglamc AJJobc. Medical and Surgical Treatment of Idiopathic Granulomatous Lobular Mastitis: A Benign Inflammatory Disease Mimicking Invasive Carcinoma. (2012) 15(1):119-23.
19. Postolova A, Troxell ML, Wapnir IL, Genovese MCJTJor. Methotrexate in the Treatment of Idiopathic Granulomatous Mastitis. (2020) 47(6):924-7.
20. Al-Jarrah A, Taranikanti V, Lakhtakia R, Al-Jabri A, Sawhney SJSQUMJ. Idiopathic Granulomatous Mastitis: Diagnostic Strategy and Therapeutic Implications in Omani Patients. (2013) 13(2):241.
21. Baslaim MM, Khayat HA, Al-Amoudi SA. Idiopathic Granulomatous Mastitis: A Heterogeneous Disease with Variable Clinical Presentation. *World journal of surgery* (2007) 31(8):1677-81.
22. Boufettal H, Essodegui F, Noun M, Hermas S, Samouh N. Idiopathic Granulomatous Mastitis: A Report of Twenty Cases. *Diagnostic and interventional imaging* (2012) 93(7-8):586-96.
23. Dağ A, Edizsoy A, Berkeşoğlu MJJoIS. Oncoplastic Breast Surgery Techniques When Surgery Is Essential for the Management of the Idiopathic Granulomatous Mastitis. (2022) 35(3):653-8.
24. Liu L, Zhou F, Zhang X, Liu S, Liu L, Xiang Y, et al. Granulomatous Lobular Mastitis: Antituberculous Treatment and Outcome in 22 Patients. *Breast Care* (2018) 13(5):359-63.
25. Néel A, Hello M, Cottureau A, Graveleau J, De Faucal P, Costedoat-Chalumeau N, et al. Long-Term Outcome in Idiopathic Granulomatous Mastitis: A Western Multicentre Study. *QJM: An International Journal of Medicine* (2013) 106(5):433-41.

26. Bani-Hani KE, Yaghan RJ, Matalka II, Shatnawi NJTbj. Idiopathic Granulomatous Mastitis: Time to Avoid Unnecessary Mastectomies. (2004) 10(4):318-22.
27. Joseph K-A, Luu X, Mor AJAoso. Granulomatous Mastitis: A New York Public Hospital Experience. (2014) 21(13):4159-63.
28. Kiyak G, Dumlu EG, Kilinc I, Tokaç M, Akbaba S, Gurer A, et al. Management of Idiopathic Granulomatous Mastitis: Dilemmas in Diagnosis and Treatment. *BMC surgery* (2014) 14(1):1-5.
29. Azlina AF, Ariza Z, Arni T, Hisham ANJWjos. Chronic Granulomatous Mastitis: Diagnostic and Therapeutic Considerations. (2003) 27(5):515-8.
30. Salehi M, Salehi M, Kalbasi N, Hakamifard A, Salehi H, Salehi MM, et al. Corticosteroid and Azithromycin in Idiopathic Granulomatous Mastitis. (2017) 6.
31. Sheybani F, Sarvghad M, Naderi H, Gharib MJO, Gynecology. Treatment for and Clinical Characteristics of Granulomatous Mastitis. (2015) 125(4):801-7.
32. Elzahaby IA, Khater A, Fathi A, Hany I, Abdelkhalek M, Gaballah K, et al. Etiologic Revelation and Outcome of the Surgical Management of Idiopathic Granulomatous Mastitis; an Egyptian Centre Experience. (2016) 36(4):115-22.
33. Montazer M, Dadashzadeh M, Toomatari SEMJAPJoCPA. Comparison of the Outcome of Low Dose and High-Dose Corticosteroid in the Treatment of Idiopathic Granulomatous Mastitis. (2020) 21(4):993.
34. Pak H, Maghsoudi LH, Soltanian A, Jafarinia SJIJoSO. Evaluation of Clinical Manifestation and Risk Factors of Idiopathic Granulomatous Mastitis. (2021) 35:100380.
35. Yildiz S, Aralasmak A, Kadioglu H, Toprak H, Yetis H, Gucin Z, et al. Radiologic Findings of Idiopathic Granulomatous Mastitis. (2015) 17(1):39-44.
36. Kayahan M, Kadioglu H, Muslumanoglu MJBC. Management of Patients with Granulomatous Mastitis: Analysis of 31 Cases. (2012) 7(3):226-30.
37. Lee JH, Oh KK, Kim E-k, Kwack KS, Jung WH, Lee HKJYmj. Radiologic and Clinical Features of Idiopathic Granulomatous Lobular Mastitis Mimicking Advanced Breast Cancer. (2006) 47(1):78-84.
38. Steuer AB, Stern MJ, Cobos G, Castilla C, Joseph K-A, Pomeranz MK, et al. Clinical Characteristics and Medical Management of Idiopathic Granulomatous Mastitis. (2020) 156(4):460-4.
39. Eroozen F, Ersoy YE, Akaydin M, Memmi N, Celik AS, Celebi F, et al. Corticosteroid Treatment and Timing of Surgery in Idiopathic Granulomatous Mastitis Confusing with Breast Carcinoma. (2010) 123(2):447-52.
40. Kehribar DY, Duran TI, Polat AK, Ozgen M. Effectiveness of Methotrexate in Idiopathic Granulomatous Mastitis Treatment. *The American Journal of the Medical Sciences* (2020) 360(5):560-5.
41. Emre A, Akbulut S, Sertkaya M, Bitiren M, Kale IT, Bulbuloglu E, et al. Idiopathic Granulomatous Mastitis: Overcoming This Important Clinical Challenge. (2018) 103(5-6):228-37.
42. Alikhassani A, Azizi F, Ensani FJJoU. Imaging Features of Granulomatous Mastitis in 36 Patients with New Sonographic Signs. (2020) 23(1):61-8.
43. Yildirim E, Kayadibi Y, Bektas S, Ucar N, Oymak A, Er AM, et al. Comparison of the Efficiency of Systemic Therapy and Intralesional Steroid Administration in the Treatment of Idiopathic Granulomatous Mastitis. The Novel Treatment for Granulomatous Mastitis. (2021) 92:234-41.
44. Barreto DS, Sedgwick EL, Nagi CS, Benveniste APJBcr, treatment. Granulomatous Mastitis: Etiology, Imaging, Pathology, Treatment, and Clinical Findings. (2018) 171(3):527-34.
45. Karanlik H, Ozgur I, Simsek S, Fathalizadeh A, Tukenmez M, Sahin D, et al. Can Steroids Plus Surgery Become a First-Line Treatment of Idiopathic Granulomatous Mastitis? *Breast care* (2014) 9(5):338-42.
46. Tekin L, Elibol FDJEJoBH. Is There Any Relationship between Granulomatous Mastitis and Seasons? An Analysis of Seasonal Frequency, Clinical, and Radiologic Findings. (2020) 16(4):235.
47. Pourzand A, Mohammadzadeh-Gharabaghi MA. Granulomatous Lobular Mastitis, a Case Series. *Journal of Research in Clinical Medicine* (2014) 2(2):83-6.
48. Vanovcanova L, Lehotska V, Machalekova K, Waczulikova I, Minarikova E, Rauova K, et al. Idiopathic Granulomatous Mastitis-a New Approach in Diagnostics and Treatment. (2019) 66(4):661-8.
49. Oak J, Nadkarni M, Shetty A, Sardar S, Kulkarni B. Methotrexate in the Treatment of Idiopathic Granulomatous Mastitis. *Indian Journal of Surgery* (2021) 83(2):454-60.
50. Atak T, Sagiroglu J, Eren T, Ali Özemir İ, Alimoglu OJBd. Strategies to Treat Idiopathic Granulomatous Mastitis: Retrospective Analysis of 40 Patients. (2015) 35(1):19-24.
51. Williams MS, McClintock AH, Bourassa L, Laya MBJEJoBH. Treatment of Granulomatous Mastitis: Is There a Role for Antibiotics? (2021) 17(3):239.
52. Jeon J, Lee K, Kim Y, Chun YS, Park HKJJoBD. Retrospective Analysis of Idiopathic Granulomatous Mastitis: Its Diagnosis and Treatment. (2017) 5(2):82-8.

53. Omranipour R, Mohammadi S-F, Samimi PJBC. Idiopathic Granulomatous Lobular Mastitis-Report of 43 Cases from Iran; Introducing a Preliminary Clinical Practice Guideline. (2013) 8(6):439-43.
54. Chirappappa P, Thaweeproradej P, Supsamutchai C, Biadul N, Lertsithichai PJAom, surgery. Idiopathic Granulomatous Mastitis: A Retrospective Cohort Study between 44 Patients with Different Treatment Modalities. (2018) 36:162-7.
55. Oran EŞ, Gürdal SÖ, Yankol Y, Öznur M, Calay Z, Tunacı M, et al. Management of Idiopathic Granulomatous Mastitis Diagnosed by Core Biopsy: A Retrospective Multicenter Study. (2013) 19(4):411-8.
56. Mahmodlou R, Dadkhah N, Abbasi F, Nasiri J, Valizadeh R. Idiopathic Granulomatous Mastitis: Dilemmas in Diagnosis and Treatment. *Electronic physician* (2017) 9(9):5375.
57. Girgin S, Uslukaya Ö, YILMAZ E, FIRAT U, Gümüş H, Kapan M, et al. Granulomatous Mastitis: A Retrospective Review of 49 Patients. (2015) 42(1):22-7.
58. Mizrakli T, Velidedeoglu M, Yemisen M, Mete B, Kilic F, Yilmaz H, et al. Corticosteroid Treatment in the Management of Idiopathic Granulomatous Mastitis to Avoid Unnecessary Surgery. (2015) 45(4):457-65.
59. Pandey TS, Mackinnon JC, Bressler L, Millar A, Marcus EE, Ganschow PSJTbj. Idiopathic Granulomatous Mastitis—a Prospective Study of 49 Women and Treatment Outcomes with Steroid Therapy. (2014) 20(3):258-66.
60. Tang A, Dominguez DA, Edquilang JK, Green AJ, Khoury AL, Godfrey RSJJoSR. Granulomatous Mastitis: Comparison of Novel Treatment of Steroid Injection and Current Management. (2020) 254:300-5.
61. Lin L, Zheng Z, Zhang J, Liu X, Chen D-R, Wang HJJoH. Treatment of Idiopathic Granulomatous Mastitis Using Ultrasound-Guided Microwave Ablation: A Report of 50 Cases. (2021) 38(1):1242-50.
62. Altintoprak F, Kivilcim T, Ozkan OV. Aetiology of Idiopathic Granulomatous Mastitis. *World Journal of Clinical Cases: WJCC* (2014) 2(12):852.
63. Tekgöz E, Çolak S, Cinar M, Yilmaz SJJJoMS. Treatment of Idiopathic Granulomatous Mastitis and Factors Related with Disease Recurrence. (2020) 50(5):1380-6.
64. Seo HRN, Na KY, Yim HE, Kim TH, Kang DK, Oh KK, et al. Differential Diagnosis in Idiopathic Granulomatous Mastitis and Tuberculous Mastitis. (2012) 15(1):111-8.
65. Kundaktepe BP, Velidedeoglu M, Mete B. The Effect of Methotrexate Monotherapy on Treatment-Resistant Idiopathic Granulomatous Mastitis Patients. *The Surgeon* (2021).
66. Deng J, Yu L, Yang Y, Feng X, Sun J, Liu J, et al. Steroids Administered after Vacuum-Assisted Biopsy in the Management of Idiopathic Granulomatous Mastitis. *Journal of Clinical Pathology* (2017) 70(10):827-31.
67. Helal TEA, Shash LS, El-Din SAS, Saber SM. Idiopathic Granulomatous Mastitis: Cytologic and Histologic Study of 65 Egyptian Patients. *Acta Cytologica* (2016) 60(5):438-44.
68. Yaghan R, Hamouri S, Ayoub NM, Yaghan L, Mazahreh T. A Proposal of a Clinically Based Classification for Idiopathic Granulomatous Mastitis. *Asian Pacific Journal of Cancer Prevention: APJCP* (2019) 20(3):929.
69. Zhang X, Li Y, Zhou Y, Liu D, Chen L, Niu K, et al. A Systematic Surgical Approach for the Treatment of Idiopathic Granulomatous Mastitis: A Case Series. *Gland Surgery* (2020) 9(2):261.
70. Akcan A, Öz AB, Dogan S, Akgün H, Akyüz M, Ok E, et al. Idiopathic Granulomatous Mastitis: Comparison of Wide Local Excision with or without Corticosteroid Therapy. *Breast Care* (2014) 9(2):111-.
71. Prasad S, Padmapriya Jaiprakash AD, Pai D. Idiopathic Granulomatous Mastitis: An Institutional Experience. *Turkish journal of surgery* (2017) 33(2):100.
72. Li J. Diagnosis and Treatment of 75 Patients with Idiopathic Lobular Granulomatous Mastitis. *Journal of Investigative Surgery* (2019) 32(5):414-20.
73. Bayrak BY, Cam I, Erucar AT, Utkan NZ. Clinicopathological Evaluation of Idiopathic Granulomatous Mastitis Patients: A Retrospective Analysis from a Tertiary Care Hospital in Turkey. *Annals of Diagnostic Pathology* (2021) 55:151812.
74. Yabanoğlu H, Çolakoğlu T, Belli S, Aytac HO, Bolat FA, Pourbagher A, et al. A Comparative Study of Conservative Versus Surgical Treatment Protocols for 77 Patients with Idiopathic Granulomatous Mastitis. *The Breast Journal* (2015) 21(4):363-9.
75. Toktas O, Konca C, Trabulus DC, Soyder A, Koksall H, Karanlik H, et al. A Novel First-Line Treatment Alternative for Noncomplicated Idiopathic Granulomatous Mastitis: Combined Intralesional Steroid Injection with Topical Steroid Administration. *Breast Care* (2021) 16(2):181-7.
76. Shojaee L, Rahmani N, Moradi S, Motamedi A, Godazandeh G. Idiopathic Granulomatous Mastitis: Challenges of Treatment in Iranian Women. *BMC surgery* (2021) 21(1):1-7.
77. Bouton ME, Jayaram L, O'Neill PJ, Hsu C-H, Komenaka IK. Management of Idiopathic Granulomatous Mastitis with Observation. *The American Journal of Surgery* (2015) 210(2):258-62.
78. Özşen M, Tolunay Ş, Gökğöz MŞ. Granulomatous Lobular Mastitis: Clinicopathologic Presentation of 90 Cases. *Age* (2018) 25(7):25-45.

79. Yücesoy C, Aydın ZB, Fidan N, Bozkurt B, Karabacak H, Eraslan Ö, et al. Radiologic Features of Idiopathic Granulomatous Mastitis and Emphasis on Analysis of Socioeconomic Status: Over 5 Years of Experience. *Indian Journal of Surgery* (2021):1-7.
80. Co M, Cheng VC, Wei J, Wong SC, Chan SM, Shek T, et al. Idiopathic Granulomatous Mastitis: A 10-Year Study from a Multicentre Clinical Database. *Pathology* (2018) 50(7):742-7.
81. KADIVAR M, RASHIDIAN S, JOLAI A, DABIRAN S. The Frequency of Idiopathic Granulomatous Mastitis and the Underlying Factors in Recent 5-Year Period. (2016).
82. Tan QT, Tay SP, Gudi MA, Nadkarni NV, Lim SH, Chuwa EWL. Granulomatous Mastitis and Factors Associated with Recurrence: An 11-Year Single-Centre Study of 113 Patients in Singapore. *World Journal of Surgery* (2019) 43(7):1737-45.
83. Davis J, Cocco D, Matz S, Hsu C-H, Brown MJ, Lee J, et al. Re-Evaluating If Observation Continues to Be the Best Management of Idiopathic Granulomatous Mastitis. *Surgery* (2019) 166(6):1176-80.
84. Koksai H. What Are the New Findings with Regard to the Mysterious Disease Idiopathic Granulomatous Mastitis? *Surgery Today* (2021) 51(7):1158-68.
85. Wang J, Zhang Y, Lu X, Xi C, Yu K, Gao R, et al. Idiopathic Granulomatous Mastitis with Skin Rupture: A Retrospective Cohort Study of 200 Patients Who Underwent Surgical and Nonsurgical Treatment. *Journal of Investigative Surgery* (2021) 34(7):810-5.
86. Aghajanzadeh M, Hassanzadeh R, Sefat SA, Alavi A, Hemmati H, Delshad MSE, et al. Granulomatous Mastitis: Presentations, Diagnosis, Treatment and Outcome in 206 Patients from the North of Iran. *The Breast* (2015) 24(4):456-60.
87. Kaviani A, Vasigh M, Omranipour R, Mahmoudzadeh H, Elahi A, Farivar L, et al. Idiopathic Granulomatous Mastitis: Looking for the Most Effective Therapy with the Least Side Effects According to the Severity of the Disease in 374 Patients in Iran. *The breast journal* (2019) 25(4):672-7.
88. Azizi A, Prasath V, Canner J, Gharib M, Sadat Fattahi A, Naser Forghani M, et al. Idiopathic Granulomatous Mastitis: Management and Predictors of Recurrence in 474 Patients. *The breast journal* (2020) 26(7):1358-62.
89. Uysal E, Soran A, Sezgin E, Group GMS. Factors Related to Recurrence of Idiopathic Granulomatous Mastitis: What Do We Learn from a Multicentre Study? *ANZ journal of surgery* (2018) 88(6):635-9.